INSERM, ERI-23, Pôle Biologie Santé, 40 Avenue du Recteur Pineau, Poitiers, France.
Antimicrob Agents Chemother. 2010 Feb;54(2):924-6. doi: 10.1128/AAC.00836-09. Epub 2009 Nov 23.
Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous (s.c.) infusions. Bioavailability was 99%+/-18% after s.c. administration, but peaks were reduced by about (43+/-29 versus 115+/-28 microg/ml) and times to peak were delayed. Simulations based on unbound concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval, suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.
在接受 1 克静脉和皮下（sc）输注的患者中比较了厄他培南的稳态药代动力学。sc 给药后的生物利用度为 99%+/-18%，但峰值降低约（43+/-29 与 115+/-28μg/ml），达峰时间延迟。基于游离浓度的模拟表明，MIC 以上的时间应始终长于给药间隔的 30%至 40%，这表明在血管通路减少的患者中，sc 输注可能是一种替代方法。
